Clinical trials: Papilloma Virus, Human
Cervical Cancers, Vulvar Cancer
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
This study will evaluate the immunogenicity and tolerability of V503 (a multivalent human papillomavirus [HPV] L1 virus-like particle [VLP] vaccine) in preadolescent and adolescent participants between 9 and 15 years old and…
- Conditions
- Cervical Cancers, Vulvar Cancer, Vaginal Cancer, Genital Lesions
- Trial name
- NCT00943722
- Testing
- V503
- Volunteers
- 3,074 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancer
Cervical Cancer Elimination -Using Implementation Science to Evaluate Deliver and Cost Introduction of Thermal Ablation
Global elimination of cervical cancer is a feasible goal; however, the countries with the greatest disease burden also have the greatest healthcare system challenges.
- Trial name
- TIBA (NCT05472311)
- Testing
- Thermal Ablation
- Where
- Kenya
- Volunteers
- 565 people, healthy volunteers welcome
- Sponsor
- University of Washington
Cervical Carcinoma, Human Papillomavirus Infection
HPV Self-Test Intervention in Ohio Appalachia
This study will pilot test a culturally appropriate human papillomavirus (HPV) self-test intervention among women from Ohio Appalachia in order to determine the feasibility of HPV self-testing as a potential cervical cancer…
- Trial name
- NCT02460237
- Testing
- Disease Screening, Educational Intervention, Informational Intervention
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
HPV Associated Cancers
Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer
This is an open-label, non-randomized, Phase I, dose escalation/dose expansion study in cohorts of patients with relapsed, resistant, or metastatic HPV-associated cancers.
- Trial name
- NCT05826275
- Testing
- TGN-S11, Pembrolizumab
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- Toragen, Inc.
External Genital Warts
Efficacy and Tolerability of Topical LFX453 for External Genital Warts
The LFX453X2202 study tested the investigational drug LFX453 against placebo for safety, tolerability, and efficacy in treating genital warts in circumcised men, in parallel with an additional open label arm using imiquimod 5%.
- Trial name
- NCT02482428
- Testing
- Investigational Treatment, Aldara
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Infections, Papillomavirus
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years
The purpose of this study is to evaluate the immunogenicity and safety of two doses of GSK Biologicals' HPV-16/18 L1 VLP AS04 vaccine when co-administered with GSK Biologicals' HAV vaccine according to 0, 6 month schedule…
- Trial name
- NCT02082639
- Testing
- Cervarix™, Havrix
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus Infection
Probiotc Lactobacillus Crispatus-M247 (Crispact®) Supplementation in the Sterilization of High-risk Human Papilloma (HPV-HR) Viruses
There is growing scientific interest in probiotic supplementation as a possible therapy for clearing the human papillomavirus (HPV) infection and reducing the risk of developement of cervical cancer.
- Trial name
- NCT06245486
- Testing
- Crispact®
- Volunteers
- 150 people
- Sponsor
- Liaquat University of Medical & Health Sciences
Condyloma
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients
This is a double-blind placebo controlled, randomized, phase 2 study to assess the safety, tolerability, pharmacokinetics and efficacy of twice daily topical applications of AP611074 5% Gel for up to 16 weeks in condyloma patients
- Trial name
- NCT02724254
- Testing
- AP611074 5% gel
- Where
- 12 sites in Argentina, Chile and 2 more
- Volunteers
- 218 people
- Sponsor
- Vaxart
Health Personnel Attitude, Health Knowledge, Attitudes, Practice
Healthcare Provider Human Papillomavirus Education and Professional Skills Intervention
Healthcare providers (HCP) serving the El Paso U.S.-Mexico Border Region will be recruited to compare educational and professional skills interventions focused on the human papillomavirus (HPV).
- Trial name
- NCT05120869
- Testing
- Tailored HPV Education and Professional Skills Intervention Group, General HPV Education and Communication Skills Control Group
- Where
- 2 sites in United States
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- University of Texas, El Paso
Human Papilloma Virus
Patient Self-sampling of HPV to Screen for Cervical Cancer
The purpose of this study is to validate a patient self-sampling vaginal collection kit and laboratory testing for the detection of HPV (human papillomavirus) infection.
- Trial name
- NCT05600283
- Testing
- Swab kit (COBAS HPV 4800 Assay -Evalyn brush), Clinician-collection of cervical sample for HPV testing
- Where
- United States
- Volunteers
- 222 people
- Sponsor
- Mayo Clinic
Human Papillomavirus Infection, Human Papillomavirus-Related Malignant Neoplasm
ESCUDDO Long Term Follow Up
This phase IV trial evaluates the long term protection provided by either one or two doses of the 9v human papillomavirus (HPV) vaccine for participants who were part of the ESCUDDO study.
- Trial name
- ESCUDDO LTFU (NCT07706673)
- Testing
- Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Recombinant Human Papillomavirus Nonavalent Vaccine
- Where
- Costa Rica
- Volunteers
- 13,700 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy
Open label Enrollment in the order of confirmation of eligibility and HPV+ tumor status Prospective stratification based on 3 factors, epidermal growth factor receptor (EGFR) mutation status, performance status and first-line…
- Trial name
- NCT02531854
- Testing
- ADXS11-001, Pemetrexed
- Sponsor
- Advaxis, Inc.
Human Papillomavirus DNA Tests, Cervical Cancer
IT-system Development for Reaching Cervix Cancer Screening Non-attenders
The main purpose is to develop and test an IT-infrastructure to provide more individualized ways of inviting and reaching women who have not participated, despite having been invited with annual reminders, in cervix cancer…
- Trial name
- NCT02750124
- Testing
- Cobas PCR Female swab sample Packet, Routine practice
- Volunteers
- 8,000 people
- Sponsor
- Karolinska Institutet
Human Papilloma Virus, Cervical Intraepithelial Neoplasia
HPV-based Screening Among Women 23-29 Years of Age
The aim of the trial is to determine whether organized screening with primary HPV analysis provide higher cancer protection in the age group 23-29 years compared to primary cytology.
- Conditions
- Human Papilloma Virus, Cervical Intraepithelial Neoplasia, Cervical Cancer
- Trial name
- NCT05229679
- Testing
- HPV testing
- Where
- 2 sites in Sweden
- Volunteers
- 180,000 people
- Sponsor
- Karolinska Institutet
Penile Squamous Cell Carcinoma (PSCC)
Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma
Penile squamous cell carcinoma (PSCC) is a highly aggressive and relatively rare disease. Supportive evidence for the value of systemic therapy does not exist for this disease and there are no agents currently approved by…
- Trial name
- NCT02541903
- Testing
- Gilotrif
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Alabama at Birmingham
Cervical Cancer, Cervical Intraepithelial Neoplasia
DNA Methylation Testing for the Screening of Uterine Cervical Lesion
In our published work, host DNA methylation testing has been proved to be sensitive and specific to cervical intraepithelial neoplasia (CIN) 2 or more severe lesions (CIN2+).
- Conditions
- Cervical Cancer, Cervical Intraepithelial Neoplasia, DNA Methylation, High-risk Human Papillomavirus
- Trial name
- NCT04646954
- Testing
- Host DNA methylation testing, Cervical cytology and/or high-risk human papillomavirus assays
- Where
- China
- Volunteers
- 12,000 people
- Sponsor
- Lei Li
Cervical Cancer, Uterine Cervical Neoplasms
Effect of Human Papillomavirus Self-Collection on Cervical Cancer Screening in High Risk Women: My Body, My Test 3
This study will investigate whether cervical cancer screening completion among under-screened women could be improved by offering HPV (human papillomavirus) testing by at-home self-collection followed by screening invitation…
- Conditions
- Cervical Cancer, Uterine Cervical Neoplasms, Human Papillomavirus
- Trial name
- MBMT-3 (NCT02651883)
- Testing
- Screening invitation (with education), Self-collection for HPV testing
- Where
- United States
- Volunteers
- 665 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Human Papilloma Virus Infection
Understanding Women's Values in Managing Human Papillomavirus (HPV)
Almost all cervical cancers are caused by infection with a high-risk (hr) HPV. In March 2020, the Scottish Cervical Screening programme changed from a test to look for abnormal cervical cells caused by hr-HPV to a test that looks…
- Trial name
- NCT06123533
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University of Aberdeen
ASC-US, Human Papilloma Virus
Can B12 and Folate Levels Predict HPV Penetration in Patients With ASCUS?
Non-classified atypical squamous cells (ASCUS) is the most common abnormal cervical cytology (%39). The risk of cervical intraepithelial neoplasia 2-3 is 5% and the risk of carcinoma is around 0.1% after diagnosis.
- Trial name
- NCT03903952
- Testing
- Vitamin B12 and folate
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sanliurfa Mehmet Akif Inan Education and Research Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.